Goldman Sachs Group Inc Taysha Gene Therapies, Inc. Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
A detailed history of Goldman Sachs Group Inc transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,205,671 shares of TSHA stock, worth $2.09 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,205,671
Previous 1,027,018
17.4%
Holding current value
$2.09 Million
Previous $2.3 Million
5.35%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding TSHA
# of Institutions
118Shares Held
136MCall Options Held
25.9KPut Options Held
24K-
Avoro Capital Advisors LLC New York, NY18.7MShares$32.3 Million0.56% of portfolio
-
Rtw Investments, LP New York, NY14.9MShares$25.9 Million0.48% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$20.3 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA10.9MShares$18.8 Million0.3% of portfolio
-
Vr Adviser, LLC New York, NY9MShares$15.6 Million1.87% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $83.7M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...